Table 3.
Comparison of clinical and biochemical variables between patients who did not develop cancer and those who developed specific types of cancer during the follow-up period.
| No cancer (n = 591) |
Uterus cancer (n = 16) |
Breast cancer (n = 11) |
Thyroid cancer (n = 10) |
Ovarian cancer (n = 9) |
ANOVA p-value |
|
|---|---|---|---|---|---|---|
| Age (years) | 55.1 ± 15.8 | 57.0 ± 1.0 | 53.3 ± 9.7 | 55.9 ± 14.9 | 58.8 ± 8.8 | ns |
| BMI (Kg/sqm) | 26.7 ± 6.4 | 28.3 ± 5.1 | 26.0 ± 5.4 | 27.2 ± 5.5 | 26.1 ± 6.4 | ns |
| Waist Circumference (cm) | 94.7 ± 15.2 | 93.2 ± 14.2 | 96.1 ± 14.4 | 94.3 ± 11.6 | 94.5 ± 13.5 | ns |
| FPG (mg/dL) | 96.4 ± 28.8 | 100.1 ± 22.4 | 99.4 ± 35.7 | 99.2 ± 36.4 | 126.1 ± 80.5* | 0.06 |
| Total Cholesterol (mg/dL) | 189.5 ± 41.5 | 196.1 ± 45.9 | 199.0 ± 43.8 | 192.5 ± 47.3 | 201.2 ± 34.5 | ns |
| HDL Cholesterol (mg/dL) | 59.1 ± 15.1 | 55.9 ± 11.0 | 59.4 ± 27.3 | 62.6 ± 16.2 | 65.6 ± 11.1 | ns |
| LDL Cholesterol (mg/dL) | 108.2 ± 33.5 | 117.6 ± 41.9 | 109.9 ± 42.0 | 109.0 ± 36.0 | 113.8 ± 35.0 | ns |
| Triglycerides (mg/dL) | 108.5 ± 63.9 | 108.5 ± 42.9 | 138.4 ± 62.6 | 105.3 ± 64.7 | 108.9 ± 46.8 | ns |
| AARPRI score | 0.5 ± 0.3 | 0.7 ± 0.4* | 1.2 ± 1.0* | 0.9 ± 0.5* | 1.3 ± 0.8* | < 0.001 |
| APRI score | 0.3 ± 0.1 | 0.4 ± 0.2* | 0.6 ± 0.5* | 0.5 ± 0.2* | 0.7 ± 0.4* | < 0.001 |
| FIB-4 score | 1.0 ± 0.6 | 1.5 ± 0.8* | 2.1 ± 2.0* | 1.5 ± 0.9* | 2.4 ± 1.5* | < 0.001 |
| mFIB-4 score | 2.0 ± 1.3 | 2.8 ± 1.6 | 4.3 ± 4.1* | 3.0 ± 1.9* | 4.9 ± 3.1* | < 0.001 |
Data is reported as mean ± SD (Standard Deviation). Comparisons between No cancer group and specific type-cancer groups were performed by Kruskal–Wallis One-Way ANOVA and p-values < 0.05 were considered significant. (*) represents significant difference with NO cancer group after Fisher’s LSD Multiple-Comparison Test.
BMI, body mass index; FPG, fasting glucose plasma; AARPRI,(AST to ALT ratio) to platelet ratio index; APRI, AST-platelet ratio index; FIB-4, fibrosis-4 index; mFIB-4, modified FIB-4.